The bill enacts R.S. 22:1028.5, which mandates health insurance coverage for biomarker testing aimed at diagnosing, treating, managing, or monitoring diseases or medical conditions. It emphasizes the importance of genomic testing and biomarker analysis in improving patient outcomes through personalized care. The bill outlines that any health coverage plan issued in Louisiana must include coverage for biomarker testing, which may be subject to standard deductibles, coinsurance, and copayment provisions. However, it clarifies that coverage for screening purposes is not required. The bill also establishes a clear process for individuals and healthcare providers to request exceptions to coverage policies.

Additionally, the bill provides definitions for key terms such as "biomarker," "biomarker testing," and "clinical utility," ensuring clarity in the application of the law. It stipulates that the provisions will apply to new health coverage plans issued after the effective date of the Act and will require existing plans to conform by their renewal date. The implementation of the bill is contingent upon a specific appropriation of funds by the Louisiana Legislature.